Breakthrough in Fight on Tick-Borne CCHF Virus Is Latest Use of New Strategy Against Diseases

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.utexas.edu/2021/11/18/breakthrough-in-fight-on-tick-borne-cchf-virus-is-latest-use-of-new-strategy-against-diseases/
Research Institution
University of Texas at Austin
Short Title
Breakthrough in Fight on Tick-Borne CCHF Virus Is Latest Use of New Strategy Against Diseases
Content Coordinator
Claudia Wair
Content Manager
Kathy Donbeck

New Study Finds Evidence of COVID Antibodies in Breast Milk of Vaccinated Mothers

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.urmc.rochester.edu/news/story/new-study-finds-evidence-of-covid-antibodies-in-breast-milk-of-vaccinated-mothers
Research Institution
University of Rochester Medical Center
Short Title
New Study Finds Evidence of COVID Antibodies in Breast Milk of Vaccinated Mothers
Content Coordinator
Claudia Wair
Content Manager
Kathy Donbeck

KU Researcher Part of Teams Developing Treatments for COVID-19, other Infectious Diseases

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
http://news.ku.edu/2021/11/11/ku-researcher-part-teams-developing-treatments-covid-19-other-infectious-diseases
Research Institution
University of Kansas
Short Title
KU Researcher Part of Teams Developing Treatments for COVID-19, other Infectious Diseases
Content Coordinator
Claudia Wair
Content Manager
Kathy Donbeck

Oral Drug Tested at Georgia State Recommended for Emergency Use Authorization to Treat COVID-19

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.gsu.edu/2021/10/01/oral-drug-tested-at-georgia-state-recommended-for-emergency-use-authorization-to-treat-covid-19/
Research Institution
Georgia State
Short Title
Oral Drug Tested at Georgia State Recommended for Emergency Use Authorization to Treat COVID-19
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.sabbiotherapeutics.com/2021/10/04/sab-biotherapeutics-announces-first-patient-dosed-in-phase-3-nih-activ-2-trial-evaluating-sab-185-for-treatment-of-covid-19/
Research Institution
SAB Biotherapeutics
Short Title
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

UTHSC Awarded $3.2 Million for Upgrades to Regional Biocontainment Laboratory

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.uthsc.edu/uthsc-awarded-3-2-million-for-upgrades-to-regional-biocontainment-laboratory/
Research Institution
University of Tennessee Health Science Center
Short Title
UTHSC Awarded $3.2 Million for Upgrades to Regional Biocontainment Laboratory
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Wesemann Receives NIAID Funding for Pan-Coronavirus Vaccine Project, NIH Director's Award

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.brighamandwomens.org/about-bwh/newsroom/awards-honors-grants-detail?id=4005
Research Institution
Brigham and Women's Hospital
Short Title
Wesemann Receives NIAID Funding for Pan-Coronavirus Vaccine Project, NIH Director's Award
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Childhood Asthma Study Uncovers Risky Air Pollutant Mixtures

INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Expands-INNOVATE-Phase-3-for-INO-4800-its-DNA-Vaccine-Candidate-for-COVID-19-to-include-Colombia-following-Regulatory-Authorization/default.aspx
Research Institution
INOVIO
Short Title
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Few Variants Arise from Acute SARS-CoV-2 Infections

Subscribe to